Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1069-1074

  Yin, Ke ^a  

^a NINGBO FIRST HOSPITAL   (China)

Author keywords

Breast cancer; Histological grading; Predictive biomarkers; SHMT2

Indexed keywords

GLYCINE HYDROXYMETHYLTRANSFERASE; SERINE HYDROXYMETHYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84929448665     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S82433     Document Type: Article

References (33)

1. Dey S, Soliman AS. Cancer in the global health era: opportunities for the Middle East and Asia. Asia Pac J Public Health. 2010;22(3 Suppl):75S–82S.
2. Wang YC, Wei LJ, Liu JT, Li SX, Wang QS. Comparison of cancer incidence between China and the USA. Cancer Biol Med. 2012;9(2):128–132.
3. Rao R, Wiechmann L. Treatment of early breast cancer. Minerva Endocrinol. 2009;34(4):311–324.
4. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–1360.
5. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract. 2014;20(1):11–28.
6. Peihong S, Perry F. Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China. Ethiop Med J. 2007;45(1):79–83.
7. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481.
8. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17(12):1545–1554.
9. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–518.
10. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn. 2004;4(2):169–188.
11. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23(Suppl 2):S52–S59.
12. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5(3):169–181.
13. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.
14. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685–698.
15. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20.
16. Pollari S, Kakonen SM, Edgren H, et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat. 2011;125(2):421–430.
17. Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346–350.
18. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869–874.
19. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040–1044.
20. di Salvo ML, Contestabile R, Paiardini A, Maras B. Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. Med Hypotheses. 2013;80(5):633–636.
21. Kit S. The biosynthesis of free glycine and serine by tumors. Cancer Res. 1955;15(11):715–718.
22. Garrow TA, Brenner AA, Whitehead VM, et al. Cloning of human cDNAs encoding mitochondrial and cytosolic serine hydroxymethyltransferases and chromosomal localization. J Biol Chem. 1993;268(16):11910–11916.
23. Anderson DD, Stover PJ. SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis. PloS One. 2009;4(6):e5839.
24. Antonov A, Agostini M, Morello M, Minieri M, Melino G, Amelio I. Bioinformatics analysis of the serine and glycine pathway in cancer cells. Oncotarget. 2014;5(22):11004–11013.
25. Lee GY, Haverty PM, Li L, et al. Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. Cancer Res. 2014;74(11):3114–3126.
26. Paone A, Marani M, Fiascarelli A, et al. SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation. Cell Death Dis. 2014;5:e1525.
27. Ye J, Fan J, Venneti S, et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 2014;4(12):1406–1417.
28. Benson JR, Weaver DL, Mittra I, Hayashi M. The TNM staging system and breast cancer. Lancet Oncol. 2003;4(1):56–60.
29. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care. 2013;8(2):149–154.
30. Dixon AR, Ellis IO, Elston CW, Blamey RW. A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer. 1991;63(4):634–635.
31. Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm. 2008;79:1–44.
32. Stover PJ, Field MS. Trafficking of intracellular folates. Adv Nutr. 2011;2(4):325–331.
33. Fu TF, Rife JP, Schirch V. The role of serine hydroxymethyltransferase isozymes in one-carbon metabolism in MCF-7 cells as determined by (13)C NMR. Arch Biochem Biophys. 2001;393(1):42–50.